Skip to Main Content

Bristol-Myers Squibb reported positive results Monday in a crucial immunotherapy trial, using a combination of the two drugs Opdivo and Yervoy to treat patients with a specific type of non-small cell lung cancer patients.

But previously undisclosed changes made by Bristol to the study, known as Checkmate-227, are raising questions about the validity and strength of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • This isn’t quite true. TMB was added as co-primary endpoint before the study enrollment stopped. PDL is still in trials which is continuing. TMB data on progression free survival showed enough impact it hit endpoint early so the data was released

Comments are closed.